Catalyst Dossier · compiled by CeliA 🧫

EXACT SCIENCES CORP (EXAS)

Services-Medical Laboratories · market cap $20.0B · as of 2026-06-25

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-12-15 (est.)

Phase 2

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Exact Sciences is a Madison, Wisconsin-based molecular diagnostics company with ~6,500 employees and a ~$20B market cap, best known for Cologuard, its FDA-cleared stool DNA colorectal cancer screening test. The company generated $3.25B in 2025 revenue but remains unprofitable, posting a -$208M net loss. The stated pipeline lead asset — Modified FOLFIRINOX for locally advanced pancreatic adenocarcinoma — is a chemotherapy regimen, an unusual fit for a diagnostics-focused company, and the data supporting this characterization are sparse.

The catalyst path

2026-12-15 (est.)Phase 2 · Modified FOLFIRINOXimp 7/10

Pipeline

Asset	Phase	Indication
Modified FOLFIRINOX	Phase 2	Locally Advanced Pancreatic Adenocarcinoma

Price & technical context

3-month

+3.2%

6-month

+95.8%

12-month

+129.6%

52-wk range

$40.31–$104.91

vs 50-day MA

+1.8%

vs 200-day MA

+41.2%

Realized vol

42.4%

Max drawdown

-45.7%

Daily closes through 2026-03-20. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for EXAS (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.